As Sanofi’s Covid-19 Sales Burst Wanes, Pandemic May Become Drag
This article is for subscribers only.
A boon to Sanofi’s profit and sales from the coronavirus outbreak will be short-lived as the pandemic hinders the drugmaker’s efforts to get some medicines to patients.
The sales burst of the first quarter, when patients stocked up on diabetes and rare-disease medicines ahead of lockdowns, is waning, the Paris-based company said Friday. The pharma giant attributed about half of its 16% profit gain to Covid-19.